Serum YKL-40 levels and disease characteristics in patients with rheumatoid arthritis by Jafari-Nakhjavani, Mohammad Reza et al.
Caspian J Intern Med 2019; 10(1):92-97  
DOI: 10.22088/cjim.10.1.92 
Short Communication 
 
 
 
 
 
 
Mohammad Reza Jafari-
Nakhjavani (MD) 1 
Amir Ghorbanihaghjo (PhD) 2 
Babak Bagherzadeh-Nobari (MD) 1 
Aida Malek-Mahdavi (PhD) 1* 
Nadereh Rashtchizadeh (PhD) 1 
 
 
 
1. Connective Tissue Diseases 
Research Center, Tabriz University 
of Medical Sciences, Tabriz, Iran 
2. Biotechnology Research Center, 
Tabriz University of Medical 
Sciences, Tabriz, Iran 
 
 
 
* Correspondence: 
Aida Malek Mahdavi: Connective 
Tissue Diseases Research Center, 
Tabriz University of Medical 
Sciences, Golgasht St., Tabriz, Iran. 
 
 
E-mail: aidamalek@gmail.com  
Tel: 0098 4133369331 
Fax: 0098 4133369315 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Received: 9 June 2018  
Revised: 16 July 2018 
Accepted: 4 Aug 2018 
 
Serum YKL-40 levels and disease characteristics in 
patients with rheumatoid arthritis 
 
 
Abstract 
Background: The present study aimed to evaluate serum YKL-40 levels in patients with 
rheumatoid arthritis (RA) compared to healthy subjects and to search whether there is an 
association between YKL-40 levels and disease characteristics in RA. 
Methods: In this cross-sectional study, 60 RA patients based on the ACR/EULAR 2010 
criteria and 30 age- and sex-matched healthy controls were included. In patients, clinical 
examination was performed and disease activity score 28 (DAS-28) measure of disease 
activity was assessed. Serum YKL-40 level was measured using ELISA kit. 
Results: The mean±SD age of patients and controls was 54.86±11.65 and 50.71±3.72 
years, respectively). Serum YKL-40 level was significantly higher in RA patients 
(951.63±639.98 pg/mL) compared to healthy controls (444.92±150.37 pg/mL) (P<0.001). 
There was no significant difference in serum YKL-40 level according to the activity of 
disease (p>0.05). There were significant positive correlations between serum YKL-40 
level with disease activity (r=0.347, P=0.007) and rheumatoid factor (r=0.396, P=0.002). 
There were no significant correlations between serum YKL-40 level with demographic 
characteristics as well as biochemical measurements including serum creatinine, blood 
urea nitrogen, erythrocyte sedimentation rate, C-reactive protein and anti-cyclic 
citrullinated peptide. 
Conclusion: Our study revealed higher serum YKL-40 levels in RA patients compared to 
healthy controls, which correlated positively with disease activity. Therefore, YKL-40 can 
be considered as a novel biomarker for disease activity estimation in RA. 
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Rheumatoid arthritis (RA) is a chronic autoimmune inflammatory synovitis that 
affects approximately 1% of the population and contributes to functional disability (1). The 
etiology of RA is unknown; however, autoimmune mechanisms play a key role in the 
pathogenesis of the disease (2). It is indicated that chronic inflammation in RA leads to 
synovial proliferation associated with cartilage and bone resorption (3). It has been 
mentioned that biochemical markers of joint tissue metabolism and disease activity would 
be very useful for monitoring the disease course in RA patients (4). Several biochemical 
markers of joint metabolism have been studied in patients with RA. Up to now, the 
erythrocyte sedimentation rate (ESR) and the serum C reactive protein (CRP) have been 
the most widely used serological parameters for long term monitoring of disease activity 
and severity of RA (5, 6).  
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However, there are differences between clinical 
inflammation and the level of ESR and serum CRP, and 
these parameters can be normal in patients with apparently 
active joint inflammation (5, 6). Therefore, new markers 
predicting clinical course and disease prognosis as well as 
following the response to treatments are of importance. 
YKL-40 is a 40-kDa heparin-human cartilage 
glycoprotein-39 without enzymatic activity that is secreted 
by various cell types in the arthritic joint (5). Its name 
derives from the one letter code for the three terminal amino 
acids - tyrosine (Y), lysine (K) and leucine (L) (7). It is a 
major protein secreted by chondrocytes in vitro and in vivo 
YKL-40 identified in the chondrocytes from arthritic knee 
joints (8-14). Furthermore, YKL-40 levels in serum and 
synovial fluids increased in joint diseases like RA (7, 15, 16) 
and osteoarthritis (OA) (17, 18), indicating that YKL-40 is a 
marker of inflammation and tissue remodeling or 
degradation (6); whereas YKL-40 is not observed in normal 
joints. Previous studies showed that serum YKL-40 levels 
correlated with clinical, laboratory, and ultrasonography 
parameters of disease activity in RA patients (5, 6, 15, 16). 
The aim of the present study was to examine serum YKL-40 
levels in patients with RA compared to healthy subjects and 
to search a correlation between serum YKL-40 
concentrations with disease characteristics in RA. 
 
 
Methods  
In current study, 60 patients aged 30 to 80 years with the 
diagnosis of RA, with disease duration ≥ 6 months, 
according to the ACR/EULAR 2010 criteria (19, 20) were 
selected consecutively from the outpatient rheumatology 
clinic of Tabriz University of Medical Sciences between 
September 2017 and February 2018. Also, 30 age- and sex 
matched healthy controls with no inflammatory rheumatic 
disease were included. The exclusion criteria were as 
follows: renal disease, liver disease, thyroid and/or 
parathyroid disorders, cardiovascular disease, diabetes 
mellitus, Cushing syndrome, any other autoimmune diseases 
or overlap syndromes, malignancies, pregnancy and 
lactation, cigarette smoking or alcoholism, taking oral 
contraceptive pills, and using vitamins, antioxidants, or other 
dietary supplements during the past 2 months prior to 
enrollment. This study was approved by the Ethics 
Committee of Tabriz University of Medical Sciences (Iran) 
and written informed consent was obtained from all subjects 
before inclusion in the study. At baseline, all participants 
were examined by a rheumatologist and the disease activity 
score 28 (DAS-28) measure of disease activity was recorded 
for patients with RA (21). Ranges of the DAS-28 score 
correspond with disease activity. A DAS-28 score of < 2.6 
indicates remission, score of 2.6 to 3.2 indicates low disease 
activity, score of 3.2 to 5.1 indicates moderate disease 
activity and score of above 5.1 is considered high disease 
activity.  
Five mL of venous blood samples was obtained after 12-
hour overnight fasting. The serum samples were separated 
from whole blood and were kept at −70°C until biochemical 
analysis. Serum YKL-40 (MyBioSource Inc., San Diego, 
CA, USA), anti-cyclic citrullinated peptide (anti-CCP) 
(Medizym., Berlin, Germany), and C-reactive protein (CRP) 
(Monobined Inc., Lake Forest, CA) levels were measured by 
ELISA according to the manufacturer’s recommendations, 
using an ELISA plate reader (Model stat fax 2100, 
Awareness, Ramsey, MN). Serum creatinine, blood urea 
nitrogen (BUN), and rheumatoid factor (RF) were measured 
by the standard enzymatic colorimetric method (Pars 
Azmoon Co, Tehran, Iran) with an automated chemical 
analyzer (Abbott analyzer, Abbott laboratories, Abbott Park, 
North Chicago, IL). The erythrocyte sedimentation rate 
(ESR) was measured using whole blood and complete blood 
counts with differential counts analyzed by the H1-
Technicon blood cell counter.  
Statistical analysis was performed using SPSS software 
version 18.0 (SPSS, Inc., USA). Normality of variables 
distribution was evaluated using the Kolmogorov-Smirnov 
test. Variables not normally distributed were analyzed using 
nonparametric tests. Categorical and normally distributed 
quantitative variables were displayed as numbers 
(percentages) and means ± SD, respectively. Non-normally 
distributed quantitative variables were presented as median 
(interquartile range). Between group comparisons were made 
by χ2, independent-sample t test, and one-way analysis of 
variance (ANOVA), as appropriate. Correlations between 
variables were analyzed by Pearson correlation test or 
Spearman rank correlation analysis. A receiver operating 
characteristic (ROC) curve analysis was performed to 
identify the optimal cut-off points of serum YKL-40 levels 
for predicting RA.  
The area under the curve (AUC) value was calculated to 
determine the accuracy of the test. A p<0.05 was considered 
statistically significant. 
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Results 
The general, clinical and biochemical characteristics of 
study subjects are shown in table 1. The mean±SD age and 
duration of disease in patients were 54.86±11.65 and 
1.99±1.22 years, respectively. The mean±SD disease activity 
and RF in patients were 4.16±1.77 and 49.63±28.07 IU/ml, 
respectively. The severity of disease according to the DAS-
28 was remission in 11 (18.4%) patients, mild in 8 (13.3%), 
moderate in 21 (35%), and high in 20 (33.3%) patients. No 
significant differences were observed in general 
characteristics between RA patients and control subjects.  
 
Table 1. Characteristics of RA patients (n=60) and 
control subjects (n=30) 
Characteristics RA patients 
 
Control 
group 
P* 
Sex, n (%) 
Male 
Female 
 
5 (8.3) 
55 (91.7) 
  
5 (16.7) 
25 (83.3) 
0.236  
 
Age (year) 54.86±11.65 50.71±3.72 0.07 
Creatinine 
(mg/dL) 
1.00±0.21 0.99±0.19 0.331 
BUN (mg/dL)  32.33±10.79 27.96±12.12 0.093 
ESR (mm/hr) 38.55±23.03 - - 
CRP (mg/L) 14.93±8.64 - - 
Anti-CCP (U) 398.5 (200, 1280) - - 
RF (n [%]) 
+1 
+2 
+3 
+4 
 
27 (45) 
20 (33.3) 
11 (18.3) 
2 (3.3) 
 
- 
- 
- 
- 
- 
 
DAS-28 4.16±1.77 - - 
RA: rheumatoid arthritis, BUN: blood urea nitrogen, ESR: erythrocyte 
sedimentation rate, CRP: C-reactive protein, Anti-CCP: anti-cyclic 
citrullinated peptide antibody, RF: rheumatoid factor, DAS-28: disease 
activity score-28.  
Data were presented as mean±SD and median (25th and 75th percentiles) for 
normally and non-normally distributed quantitative measures, respectively 
or number (percent) for categorical variables. 
* p values indicate comparison between groups (χ2 or independent-sample t 
test, as appropriate). 
 
As presented in figure 1, serum YKL-40 level was 
significantly higher in RA patients (951.63±639.98 pg/mL) 
compared to healthy controls (444.92±150.37 pg/mL) 
(p<0.001).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. Serum concentrations of YKL-40 in RA 
patients (n=60) and control group (n=30). Values are 
means±SD (*Independent-sample t test for between 
group comparison, P<0.001). 
 
Figure 2 demonstrates serum YKL-40 levels in RA 
patients based on DAS-28 score. There was no significant 
difference in serum YKL-40 level according to the activity 
of disease (p>0.05). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. Comparison of serum YKL-40 levels based on 
DAS-28 score in RA patients (n=60). Values are means ± 
SD (*One-way ANOVA for between group comparison, 
P=0.066). 
 
As illustrated in figures 3 and 4, there were significant 
positive correlations between serum YKL-40 level with 
disease activity (r=0.347, p=0.007) and RF (r=0.396, 
p=0.002).  
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There were no significant correlations between serum 
YKL-40 level with demographic characteristics as well as 
biochemical measurements including serum creatinine, 
BUN, ESR, CRP and anti-CCP (p>0.05).   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3. Correlation between serum concentrations of 
YKL-40 and DAS-28 in RA patients (n=60). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4. Correlation between serum concentrations of 
YKL-40 and RF in RA patients (n=60). 
 
The ability of serum YKL-40 concentrations to 
distinguish patients with RA from those without RA was 
assessed using ROC curve analysis (figure 5). ROC curve 
was well above the diagonal, indicating good sensitivity and 
specificity.  
The ROC curve for the presence of RA diagnosis had an 
AUC of 0.797 (95% CI: 0.704–0.890, p<0.001) which 
indicated a high probability of correctly prediction of RA. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5. Receiver operating characteristic (ROC) curve 
analysis for predictive values of serum concentrations of 
YKL-40 in RA. The area under the ROC curve is 0.797; 
95% CI: 0.704–0.890, p<0.001. 
 
 
Discussion 
RA is an autoimmune disorder in which chronic active 
inflammation leads to synovial proliferation of cartilage and 
bone (22). A wide range of serum markers were used to 
measure disease activity in RA patients, however, there was 
no single biomarker that could demonstrate the biology of 
disease and to help predict clinical course. Therefore, there is 
still a need for specific novel biomarker of synovial 
inflammation and disease activity. YKL-40 is considered as 
a possible new biomarker. It is assumed that YKL-40 is a 
candidate autoantigen in RA, suggesting to play a pathogenic 
role in the inflammatory process and joint destruction. 
In the present study, we found that serum YKL-40 was 
elevated in patients with RA compared to healthy subjects 
and correlated with the disease activity as measured by 
DAS-28 score which was similar to previous studies (5, 6, 
12, 15, 23, 24). In another study, it was shown that patients 
with clinically active RA that became inactive during the 
one-year study period had a significant decrease in serum 
YKL-40 level, whereas patients whose RA remained 
clinically active showed an increase in serum YKL-40 level. 
This study confirmed that serum YKL-40 was influenced by 
the disease activity in RA and behaved as another acute 
phase reactant, like serum hsCRP and ESR (16). These 
findings were also supported by previous report in which 
YKL-40 levels were high in severe RA (25). Furthermore, 
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YKL-40 can have a role in cartilage destruction in arthritic 
joints and that serum YKL-40 may reflect a combination of 
cartilage metabolism and a more local aspect of the 
inflammatory process than serum CRP and ESR in patients 
with RA. It has been noticed that different cells including 
synovial cells, chondrocytes, osteoblasts, macrophages, and 
neutrophils produce serum YKL-40 in RA patients, but it is 
difficult to recognize which cells are responsible for the 
increase in serum YKL-40 levels. 
Based on our study, there were no significant correlations 
between serum YKL-40 with serum CRP and ESR which 
was in contrast with previous investigations (15, 16, 23, 25, 
26). Several pathological conditions affect these parameters; 
therefore, these laboratory parameters are non-specific 
indicators of synovial inflammation (7). Our study was 
consistent with Johansen et al.’s (27) study who also did not 
find positive correlations between serum CRP and YKL-40 
levels in OA patients. This discrepancy between our findings 
with previous studies might be due to the differences in 
studied population, disease duration, baseline disease activity 
and YKL-40 status as well as type, dosage and duration of 
medical therapies. The present study has the following 
limitations: (i) the relatively small sample size and (ii) 
patients were treated with immunosuppressive therapies, 
such as steroids, at the time point of investigation and blood 
sampling which may affect the results. The strength of this 
study was that we had an age- and sex-matched control 
group and compared mean serum YKL-40 levels between 
patients with RA and normal subjects.  
In conclusion, our study revealed higher serum YKL-40 
levels in RA patients compared to healthy controls, which 
correlated positively with disease activity. Therefore, YKL-
40 can be considered as a novel biomarker for disease 
activity estimation in RA.  
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